Malu Martínez-Chantar
mlmartinez
Malu Martínez-Chantar
PRINCIPAL INVESTIGATOR
Liver Disease Lab
Address: Bizkaia Science and Technology Park, building 801A, Derio (Bizkaia)

Malu Martinez Chantar has an extensive experience in the study of liver biology, particularly NAFLD, to which she has dedicated all of her professional career. She has a very high-level track of record productivity with publications in a very high-percentage of publications of the 1st decile in the category of Nature, Nature Communications, Cell Metabolism, Hepatology and Gastroenterology. Since 2005, when she initiated her laboratory as a Principal Investigator and got “tenure” at CIC bioGUNE, Spain, her  laboratory work has been continuously financially supported by government and private funding competitive sources, both national and international. Remarkably, she has been co-PI of NIH with Dr. Lu (USC, Keck School of Medicine, Los Angeles, USA) in the field of liver disease. She was one of the partners in an ambitious European project so called HEPADIP Consortium, which was created in response to the topic of the 3rd call for proposals in the EU FP6 Programme. Actually, she is the coordinator of the Traslational Area of the National Institute for the study of Liver and Gastrointestinal Diseases (CIBEREHD) and the Scientific Advisory Board of national and international centers. Finally, she is part of the select multinational group "Women in Hepatology" composed only of women, experts in the field of Hepatology, with representatives from Europe and USA.

She has also held several collaborations with Pharmaceutical companies with 5 resultant patent applications and 4 licensed products. Finally, she has maintained a closed collaboration with the company OWL Metabolomics in the development of OWLiver® Care and OWLiver®, two non-invasive assays for fatty liver screening and for NASH diagnosis.

Latest Publications

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

Latest Publications

Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

Simon, J;Goikoetxea-Usandizaga, N;Serrano-Macia, M;Fernandez-Ramos, D;de Urturi, DS;Gruskos, JJ;Fernandez-Tussy, P;Lachiondo-Ortega, S;Gonzalez-Recio, I;Rodriguez-Agudo, R;Gutierrez-de-Juan, ...

JOURNAL OF HEPATOLOGY

2021-07-01

Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury

Iruzubieta, P;Goikoetxea-Usandizaga, N;Barbier-Torres, L;Serrano-Macia, M;Fernandez-Ramos, D;Fernandez-Tussy, P;Gutierrez-de-Juan, V;Lachiondo-Ortega, S;Simon, J;Bravo, M;Lopitz-Otsoa, F;Robles, ...

JHEP REPORTS

2021-06-01

E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

Gonzalez-Romero, F;Mestre, D;Aurrekoetxea, I;O'Rourke, CJ;Andersen, JB;Woodhoo, A;Tamayo-Caro, M;Varela-Rey, M;Palomo-Irigoyen, M;Gomez-Santos, B;de Urturi, DS;Nunez-Garcia, M;Garcia-Rodriguez, ...

CANCER RESEARCH

2021-06-01

Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

Colyn, L;Barcena-Varela, M;Alvarez-Sola, G;Latasa, MU;Uriarte, I;Santamaria, E;Herranz, JM;Santos-Laso, A;Arechederra, M;de Gauna, MR;Aspichueta, P;Canale, M;Casadei-Gardini, A;Francesconi, ...

HEPATOLOGY

2021-06-01

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

Fernandez-Tussy, P;Rodriguez-Agudo, R;Fernandez-Ramos, D;Barbier-Torres, L;Zubiete-Franco, I;de Davalillo, SL;Herraez, E;Goikoetxea-Usandizaga, N;Lachiondo-Ortega, S;Simon, J;Lopitz-Otsoa, F;Gutierrez-de ...

CELL DEATH & DISEASE

2021-05-28

Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals

Egia-Mendikute, L;Bosch, A;Prieto-Fernandez, E;Lee, SY;Jimenez-Lasheras, B;del Rio, AG;Antonana-Vildosola, A;Bruzzone, C;Bizkarguenaga, M;Embade, N;Gil-Redondo, R;Martinez-Chantar, ML;Lopez-Hoyos, ...

COMMUNICATIONS BIOLOGY

2021-04-20

The phenotypic and genetic spectrum of patients with heterozygous mutations in cyclin M2 (CNNM2)

Franken, GAC;Muller, D;Mignot, C;Keren, B;Levy, J;Tabet, AC;Germanaud, D;Tejada, MI;Kroes, HY;Nievelstein, RAJ;Brimble, E;Ruzhnikov, M;Claverie-Martin, F;Szczepanska, M;Cuk, M;Latta, F;Konrad, ...

HUMAN MUTATION

2021-03-01

Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease

Martinez-Chantar, ML;Delgado, TC;Beraza, N

FRONTIERS IN IMMUNOLOGY

2021-02-18

Glutamine, fatty liver disease and aging

Simon, J;Martinez-Chantar, ML;Delgado, TC

AGING-US

2021-02-15

Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

Lee-Law, PY;Olaizola, P;Caballero-Camino, FJ;Izquierdo-Sanchez, L;Rodrigues, PM;Santos-Laso, A;Azkargorta, M;Elortza, F;Martinez-Chantar, ML;Perugorria, MJ;Aspichueta, P;Marzioni, M;LaRusso, ...

JOURNAL OF HEPATOLOGY

2021-02-01